Where is Lucence located?

Lucence is headquartered in Singapore, Singapore. It is registered at 211 HENDERSON ROAD #04-02 211 HENDERSON SINGAPORE 159552.

Which legal entities is Lucence associated with?

Lucence is associated with Lucence Life Sciences Pte. Ltd. and 1 other.

How many employees does Lucence have?

As of Apr 30, 2026, the latest employee count at Lucence is 111.

Is Lucence a funded company?

Lucence is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does Lucence rank among its competitors?

Lucence ranks 131st amongst 390 active competitors, of which 130 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Caris Life Sciences, which secured $168M in Apr, 2025.

Who are the top competitors of Lucence?

Lucence's top competitors include Denali Therapeutics, Caris Life Sciences and Personalis. Among them, Caris Life Sciences secured the most recent funding round in April, 2025.

Lucence - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Lucence is a developer of genomic tests for the treatment of cancer. It has developed precision oncology genomic tests that is non-invasive blood tests that help in the detection and improve treatment selection. Genomic medicines help in the detection of cancer before symptoms show and check for genetic risk of developing cancer. It has developed a SAFER Sample that is a proprietary formula of virus transport medium that preserves viral ribonucleic acids at room temperature for up to a week without the need for chilling. It is a non-invasive specimen collection & helps in the transport of samples. The product is compatible with qPCR testing procedures.

Website: www.lucence.com/
Social
Email ID: *****@lucence.com
Phone Number: +65 **********
Registered Address: 211 HENDERSON ROAD #04-02 211 HENDERSON SINGAPORE 159552

Key Metrics

Founded Year

1999

Location

Singapore, Singapore

Stage

Funding Raised

Investors

Openspace Capital & 1 more

Ranked

131^st among 390 active competitors

Employee Count

111 as on Apr 30, 2026

Similar Companies

Denali Therapeutics & 534 more

View Lucence's full profile

Lucence is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Lucence Diagnostics Pte Ltd CIN: 201605840N , Singapore, Active	Dec 31, 2015	-	-
Lucence Life Sciences Pte. Ltd. CIN: 201816193K , Singapore, Active		-	-

Lucence is a funded company. Lucence has 2 institutional investors.

View details of Lucence's funding rounds and investors

The founders of Lucence is Min-Han Tan.

Here are the details of Lucence's key team members:

Min-Han Tan: Founder & CEO of Lucence and founder of 1 other company. They serve on the board of 1 company.

Lucence's Board of Directors

Lucence's board has 3 active members. Min-Han Tan and Tan Kim Lee are part of team and Lim Kaling is independent board member.

Here is the list of Lucence's board of directors:

Name	Type	Representing	Status	Duration
Min-Han Tan	Team	-	Current	10y 2m
twsdp{w	Team	-	Current	1y 3m
Lim Kaling	Independent board member	-	Current	6y 6m
axsomgg	Independent board member	-	Past	6y 9m
nyjlzi{	Independent board member	-	Past	6y 7m

View details of Lucence's Founder profiles and Board Members

Lucence's employee count trend

Lucence has 111 employees as of Apr 26. Here is Lucence's employee count trend over the years:

Uncover Lucence's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Lucence include Denali Therapeutics, Caris Life Sciences and Personalis. Here is the list of Top 10 competitors of Lucence, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Denali Therapeutics 2015, San Francisco (United States), Public	Developer of therapies to treat neurodegenerative diseases	$347M	Baillie Gifford, Bezos Expeditions & 10 others	72/100
2nd	Caris Life Sciences 1996, Irving (United States), Public	Developer of panomic disease profiling technologies for cancer precision medicine	$1.23B	Sixth Street, Braidwell & 19 others	71/100
3rd	Personalis 2011, Menlo Park (United States), Public	Provider of genomic sequencing and diagnosis software for the healthcare industry	$87.3M	Abingworth, Lightspeed Venture Partners & 5 others	70/100
4th	Geneoscopy 2015, St. Louis (United States), Series C	Developer of non-invasive biomarker tests for colorectal cancer	$219M	LightChain Capital, Cultivation Capital & 18 others	67/100
5th	Intellia Therapeutics 2014, Cambridge (United States), Public	Developer of therapeutics based on CRISPR/Cas9 technology for multiple diseases	$85M	Orbimed, Novartis & 10 others	66/100
6th	Unilabs 2000, Geneva (Switzerland), Acquired	Provider of diagnostics services company	-	Digital Pharma Lab, Nordic Capital & 1 others	65/100
7th	ACT Genomics 2014, Taipei (Taiwan), Acquired	Clinical and research services in genomics for cancer	$20.5M	Hotung Investment Holdings, CLSA Capital Partners ... & 9 others	64/100
8th	Deep Genomics 2014, Toronto (Canada), Series C	AI-powered platform for RNA biology to accelerate genetic therapy discovery	$238M	SoftBank Vision Fund, Khosla Ventures & 16 others	63/100
9th	Precipio Diagnostics 1997, New Haven (United States), Public	Provider of cancer diagnostics and second opinion tools	$800K	Ironwood Capital, Enhanced Capital & 3 others	63/100
10th	NeoGenomics 2002, Fort Myers (United States), Public	Provider of cancer genetic diagnostic services	-	Ranger Investments, Aspen Capital & 1 others	63/100
131st	Lucence 1999, Singapore (Singapore), Funding Raised	Developer of genomic tests for the treatment of cancer	-	Openspace Capital, Centurion Investment Management	39/100